Mark T J van Bussel

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Brain Metastases

Systematic Review

Cerebrospinal Fluid

Top Venues

Pharmacology research & perspectives

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Marc Maliepaard, Yoran S Faber, Mark T J van Bussel
Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency. Pharmacology research & perspectives 11 (2) (2023)
Marc Maliepaard, Yoran S Faber, Mark T J van Bussel
Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency. Pharmacology research & perspectives 11 (2) (2023)
Mark T J van Bussel, Dick Pluim, Bojana Milojkovic Kerklaan, Mijke Bol, Karolina Sikorska, Dorothé T C Linders, Daan van den Broek, Jos H Beijnen, Jan H M Schellens, Dieta Brandsma
Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. Neurology 94 (5) (2020)
Mark T J van Bussel, Ahmad Awada, Maja J A de Jonge, Morten Mau Sorensen, Dorte Nielsen, Patrick Schöffski, Henk M W Verheul, Barbara Sarholz, Karin Berghoff, Samer El Bawab, Mirjam Kuipers, Lars Damstrup, Ivan Diaz-Padilla, Jan H M Schellens
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. British journal of cancer 124 (4) (2020)
Mark T J van Bussel, Jos H Beijnen, Dieta Brandsma
Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. BMC cancer 19 (1) (2019)